Dr. Gu is a nanotechnology engineer, expert in the development of nanotherapeutics and diagnostic modalities targeting human and animal diseases. His research on the formulation of disease-targeted nanoparticles has generated over 20 papers, and 15 US and World pending patent applications. His technologies related to the precise engineering of therapeutic nanoparticles have been licensed to several biotechnology companies including BIND Biosciences and Selecta Biosciences as their core technologies for the manufacturing of clinical grade targeted nanoparticles. Frank Gu’s Laboratory has recently developed reusable nanoparticles that can target and capture protein and nucleic acid biomarkers at picogram concentration in vitro. Such technologies may be used for recovering unique targets for genomics and proteomics applications.

Frank Gu received his Ph.D. in Chemical Engineering at Queen’s University in Canada. During his Ph.D. program, he was awarded the Japanese Society the Promotion of Science (JSPS) summer fellowship to work on nanoparticle formulation at the University of Tokyo. In 2006, he was award with NSERC Postdoctoral Fellowship to join the Laboratory of Professor Robert Langer lab at Massachusetts Institute of Technology (MIT), where he pursued in-depth research training in nanomedicine and drug delivery. Dr. Gu joined the Department of Chemical Engineering at the University of Waterloo, and was subsequently cross-appointed to the Waterloo Institute of Nanotechnology. His current research interests are in the development of nanotherapeutics and diagnostic modalities targeting human and animal diseases.